- Trials with a EudraCT protocol (38,621)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
38,621 result(s) found for: decitabine OR 2.
Displaying page 102 of 1,932.
EudraCT Number: 2013-004235-77 | Sponsor Protocol Number: XILO-FIST | Start Date*: 2015-01-02 | ||||||||||||||||
Sponsor Name:NHS Greater Glasgow & Clyde [...] | ||||||||||||||||||
Full Title: Xanthine oxidase inhibition for improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST). | ||||||||||||||||||
Medical condition: Ischaemic stroke or transient ischaemic attack (TIA) (ICD Classification Code I63.0-9 and G45.0-1) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000078-21 | Sponsor Protocol Number: 1014201 | Start Date*: 2015-04-08 |
Sponsor Name:CHU Toulouse | ||
Full Title: | ||
Medical condition: | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003350-99 | Sponsor Protocol Number: Ringerfundin-01/2005 | Start Date*: 2005-08-26 |
Sponsor Name:B. Braun Medical s.r.o. | ||
Full Title: METABOLIC EFFECT OF RINGERFUNCIN B. BRAUN IN HEALTHY VOLUNTEERS AND COMPARISON WITH IONIC SOLUTION PLASMA-LYTE BAXTER | ||
Medical condition: healthy voluntaries | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002877-20 | Sponsor Protocol Number: C17-315-04 | Start Date*: 2018-03-28 | |||||||||||
Sponsor Name:Lytix Biopharma AS | |||||||||||||
Full Title: An open-label phase II single-centre study investigating the safety and efficacy of LTX-315 and adoptive T-cell therapy in patients with advanced/metastatic soft tissue sarcoma | |||||||||||||
Medical condition: Soft tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001098-34 | Sponsor Protocol Number: I6T-MC-AMAF | Start Date*: 2016-10-31 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Protocol I6T-MC-AMAF A Phase 2, Multicenter, Randomized, Parallel-arm, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001247-12 | Sponsor Protocol Number: 20-001 | Start Date*: 2021-03-30 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: An Open Label, Phase IV, Mechanistic, Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin treatment in Type 2 Diabetes Mellitus Patients with Impaired Renal Function | |||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) with impaired renal function | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000375-16 | Sponsor Protocol Number: Verges-HorsAOI2012 | Start Date*: 2012-04-12 |
Sponsor Name:CHU Dijon | ||
Full Title: Effect of Liraglutide on fatty liver content evaluated by 1H-spectroscopy and lipoprotein kinetic, in patients with type 2 diabetes | ||
Medical condition: | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-003481-41 | Sponsor Protocol Number: CPH-201-201461 | Start Date*: 2020-01-17 | |||||||||||
Sponsor Name:Croma-Pharma GmbH | |||||||||||||
Full Title: A Double-Blinded Randomized Controlled Study to Compare the Efficacy, Time to Onset, and Duration of Effect of Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines | |||||||||||||
Medical condition: moderate to severe glabellar frown lines at maximum frown | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005176-17 | Sponsor Protocol Number: BP-I-008 | Start Date*: 2016-10-20 | |||||||||||
Sponsor Name:Bellicum Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase I Study of Safety, Pharmacokinetics and Efficacy of Donor BPX-501 Cells and AP1903 Infusion for Children with Recurrent or Minimal Residual Disease Hematologic Malignancies After Allogeneic... | |||||||||||||
Medical condition: recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004568-72 | Sponsor Protocol Number: ASTX029-01 | Start Date*: 2021-05-27 | ||||||||||||||||||||||||||
Sponsor Name:Astex Pharmaceuticals, Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects with Advanced Solid Tumors | ||||||||||||||||||||||||||||
Medical condition: Advanced Solid Tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Completed) ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2024-000261-24 | Sponsor Protocol Number: ECT-001-CB.007 | Start Date*: 2024-06-24 |
Sponsor Name:Cordex Biolohics Inc | ||
Full Title: A Phase I/II Open-Label Study of ECT-001-Expanded Cord Blood Transplantation in pediatric and young adult (<21year) Patients with High-Risk and Very High-Risk Myeloid Malignancies (ECT-001-CB.007) | ||
Medical condition: High-Risk and Very High-Risk Paediatric Myeloid Malignancies | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2017-000900-38 | Sponsor Protocol Number: FT01CARCIK | Start Date*: 2017-08-16 | |||||||||||
Sponsor Name:FONDAZIONE TETTAMANTI M.DE MARCHI ONLUS | |||||||||||||
Full Title: Open label, single arm, multicenter, dose escalation Phase I-IIa, trial to determine the safety of Allogeneic (donor derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 C... | |||||||||||||
Medical condition: Relapsed or Refractory B cell Acute Lymphoblastic Leukemia after Haematopoietic Stem Cell Transplantation | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-006011-23 | Sponsor Protocol Number: 130669 | Start Date*: 2021-03-02 |
Sponsor Name:Petra Pietarinen | ||
Full Title: Laryngeaalisen leukoplakian mikrobilääkehoito -tutkimusprojekti | ||
Medical condition: Krooninen laryngiitti | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: | |
Trial protocol: FI (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2023-000126-29 | Sponsor Protocol Number: SZÚ/00127/2023 | Start Date*: 2023-04-21 |
Sponsor Name:Státní zdravotní ústav | ||
Full Title: Pilot Study of Combined PDT and SDT Efficacy In Vivo in Human Volunteers for Application in Hygiene and Clinical Practice | ||
Medical condition: Antimicrobial efficacy of combined PDT and SDT on the skin | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-002893-76 | Sponsor Protocol Number: PRAGUE-10 | Start Date*: 2008-02-13 |
Sponsor Name:Charles University in Prague, Third Faculty of Medicine | ||
Full Title: MEtabolic Therapy with Trimetazidine in Acute heart failure: an open pilot randomized trial (The METTA – PRAGUE 10 Trial) | ||
Medical condition: Acute Heart Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002803-81 | Sponsor Protocol Number: TREX | Start Date*: 2020-04-03 | |||||||||||
Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: Neurodevelopmental outcome after standard dose sevoflurane versus low-dose sevoflurane/dexmedetomidine/remifentanil anaesthesia in young children | |||||||||||||
Medical condition: Children under the age of 2 years having surgery lasting at least 2 hours | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2024-000422-17 | Sponsor Protocol Number: C3671016 | Start Date*: 2024-08-26 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 1, OPEN-LABEL, AGE DESCENDING, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE (RSVpreF) IN CHILDREN ... | |||||||||||||
Medical condition: Prevention of RSV-associated lower respiratory tract illness in children 2-18 years of age by active immunization | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003484-22 | Sponsor Protocol Number: PNC+AHEP | Start Date*: 2012-09-11 |
Sponsor Name:Helsinki University Central Hospital | ||
Full Title: Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantly | ||
Medical condition: 18 years old or older volunteers with general good health | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011158-17 | Sponsor Protocol Number: Hebe-2_10-02-2009 | Start Date*: 2009-08-20 |
Sponsor Name:Erasmus MC | ||
Full Title: Additional treatment to primary PCI: effects of ischemic postconditioning and Exenatide. | ||
Medical condition: Patients with a large myocardial infarction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000079-18 | Sponsor Protocol Number: PHN-BBFC-NI101 | Start Date*: 2020-03-18 | |||||||||||||||||||||
Sponsor Name:Pharmathen S.A. | |||||||||||||||||||||||
Full Title: A phase III, multicentre, prospective, randomized, assessor-blinded, two-arm, parallel group, therapeutic non-inferiority 3-month clinical trial to compare the efficacy and safety of a generic fixe... | |||||||||||||||||||||||
Medical condition: Open-angle glaucoma (OAG) or ocular hypertension (OHT) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GR (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
